nach oben

Erschienen in:

01.09.2007 | Populations at Risk

Barriers to Obtaining Waivers to Prescribe Buprenorphine for Opioid Addiction Treatment Among HIV Physicians

verfasst von: Chinazo O. Cunningham, MD, Hillary V. Kunins, MD, MPH, MS, Robert J. Roose, MD, MPH, Rashiah T. Elam, MD, Nancy L. Sohler, PhD, MPH

Erschienen in: Journal of General Internal Medicine | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Illicit drug use is common among HIV-infected individuals. Buprenorphine enables physicians to simultaneously treat HIV and opioid dependence, offering opportunities to improve health outcomes. Despite this, few physicians prescribe buprenorphine.

Objective

To examine barriers to obtaining waivers to prescribe buprenorphine.

Design

Cross-sectional survey study.

Participants

375 physicians attending HIV educational conferences in six cities in 2006.

Approach

Anonymous questionnaires were distributed and analyzed to test whether confidence addressing drug problems and perceived barriers to prescribing buprenorphine were associated with having a buprenorphine waiver, using chi-square, t tests, and logistic regression.

Results

25.1% of HIV physicians had waivers to prescribe buprenorphine. In bivariate analyses, physicians with waivers versus those without waivers were less likely to be male (51.1 vs 63.7%, p < .05), more likely to be in New York (51.1 vs 29.5%, p < .01), less likely to be infectious disease specialists (25.5 vs 41.6%, p < .05), and more likely to be general internists (43.6 vs 33.5%, p < .05). Adjusting for physician characteristics, confidence addressing drug problems (adjusted odds ratio [AOR] = 2.05, 95% confidence interval [95% CI] = 1.08–3.88) and concern about lack of access to addiction experts (AOR = 0.56, 95% CI = 0.32–0.97) were significantly associated with having a buprenorphine waiver.

Conclusions

Among HIV physicians attending educational conferences, confidence addressing drug problems was positively associated with having a buprenorphine waiver, and concern about lack of access to addiction experts was negatively associated with it. HIV physicians are uniquely positioned to provide opioid addiction treatment in the HIV primary care setting. Understanding and remediating barriers HIV physicians face may lead to new opportunities to improve outcomes for opioid-dependent HIV-infected patients.

Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 2005, vol. 17. 2006. Atlanta Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2006, 1–47. Accessed 20 Jan 2007 at http://www.cdc.gov/hiv/topics/surveillance/resources/reports/.

Fleishman JA, Gebo KA, Reilly ED, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000–2002. Med Care. 2005;43(9 suppl):40–52.

Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281(24):2305–15.PubMedCrossRef

Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.PubMed

Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999;131(2):81–7.PubMed

Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27(3):251–9.PubMed

Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–74.PubMedCrossRef

Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction. 2004;99(3):361–8.PubMedCrossRef

Department of Health and Mental Hygiene. New York City HIV/AIDS annual surveillance statistics. New York: New York City Department of Health and Mental Hygiene; 2006. Accessed 25 Jan 2007 at http://www.nyc.gov/html/doh/html/ah/hivtables.shtml (Updated 4 Dec 2006).

10.

Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med. 2001;161(1):85–91.PubMedCrossRef

11.

Selwyn PA, Budner NS, Wasserman WC, Arno PS. Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. Public Health Rep. 1993;108(4):492–500.PubMed

12.

Department of Health and Human Services Substance Abuse and Mental Health Services Administration. Results from the 2005 National Survey on Drug Use and Health: detailed tables. Rockville, Md: Department of Health and Human Services Substance Abuse and Mental Health Services Administration, Office of Applied Sciences; 2006. Accessed 20 Jan 2007 at http://oas.samhsa.gov/NSDUH/2k5nsduh/tabs/2k5TabsCover.pdf.

13.

Office of National Drug Control Policy. Consultation document on opioid agonist treatment; 2003. Accessed 20 Jan 2007 at http://www.whitehousedrugpolicy.gov/science%5Ftech/methadone/metha3.html.

14.

Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006;25(4):91–103.PubMedCrossRef

15.

Saitz R, Friedmann PD, Sullivan LM, et al. Professional satisfaction experienced when caring for substance-abusing patients: faculty and resident physician perspectives. J Gen Intern Med. 2002;17(5):373–6.PubMed

16.

Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med 2005;165(15):1769–76.PubMedCrossRef

17.

Johnson TP, Booth AL, Johnson P. Physician beliefs about substance misuse and its treatment: findings from a U.S. survey of primary care practitioners. Subst Use Misuse. 2005;40(8):1071–84.PubMedCrossRef

18.

Friedmann PD, McCullough D, Saitz R. Screening and intervention for illicit drug abuse: a national survey of primary care physicians and psychiatrists. Arch Intern Med. 2001;161(2):248–51.PubMedCrossRef

19.

Geller G, Levine DM, Mamon JA, Moore RD, Bone LR, Stokes EJ. Knowledge, attitudes, and reported practices of medical students and house staff regarding the diagnosis and treatment of alcoholism. JAMA. 1989;261(21):3115–20.PubMedCrossRef

20.

Cunningham CO, Sohler NL, McCoy K, Kunins HV. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38(5):336–40.PubMed

21.

Sullivan LE, Tetrault J, Bangalore D, Fiellin DA. Training HIV physicians to prescribe buprenorphine for opioid dependence. Subst Abuse. 2006;27(3):13–18.CrossRef

22.

Becker WC, Fiellin DA. Provider satisfaction with office-based treatment of opioid dependence. A systematic review. Subst Abuse. 2006;26(1):15–22.CrossRef

23.

West JC, Kosten TR, Wilk J, et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict. 2004;13(suppl 1):S8–16.PubMedCrossRef

24.

Chappel JN, Veach TL, Krug RS. The substance abuse attitude survey: an instrument for measuring attitudes. J Stud Alcohol. 1985;46(1):48–52.PubMed

25.

Hosmer DW, Lemeshow S. Applied logistic regression, 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2000.

26.

Friedmann PD, McCullough D, Chin MH, Saitz R. Screening and intervention for alcohol problems. A national survey of primary care physicians and psychiatrists. J Gen Intern Med. 2000;15(2):84–91.PubMedCrossRef

27.

Gottlieb NH, Mullen PD, McAlister AL. Patients’ substance abuse and the primary care physician: patterns of practice. Addict Behav. 1987;12(1):23–32.PubMedCrossRef

28.

Ford C, Ryrie IA. A comprehensive package of support to facilitate the treatment of problem drug users in primary care: an evaluation of the training component. Int J Drug Policy. 2000;11(6):387–92.PubMedCrossRef

29.

Miller NS, Sheppard LM, Colenda CC, Magen J. Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Acad Med. 2001;76(5):410–18.PubMedCrossRef

30.

Park ER, Wolfe TJ, Gokhale M, Winickoff JP, Rigotti NA. Perceived preparedness to provide preventive counseling: reports of graduating primary care residents at academic health centers. J Gen Intern Med. 2005;20(5):386–91.PubMedCrossRef

31.

Isaacson JH, Fleming M, Kraus M, Kahn R, Mundt M. A national survey of training in substance use disorders in residency programs. J Stud Alcohol. 2000;61(6):912–15.PubMed

32.

Fleming MF, Manwell LB, Kraus M, Isaacson JH, Kahn R, Stauffacher EA. Who teaches residents about the prevention and treatment of substance use disorders? A national survey. J Fam Pract. 1999;48(9):725–29.PubMed

33.

Fleming M, Barry K, Davis A, Kropp S, Kahn R, Rivo M. Medical education about substance abuse: changes in curriculum and faculty between 1976 and 1992. Acad Med. 1994;69(5):362–9.PubMedCrossRef

34.

SAMHSA/CSAT. SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program. Presented at the American Society of Addiction Medicine, May 2006. Accessed 24 May 2007 at http://buprenorphine.samhsa.gov/ASAM_06_Final_Results.pdf.

Titel: Barriers to Obtaining Waivers to Prescribe Buprenorphine for Opioid Addiction Treatment Among HIV Physicians
verfasst von: Chinazo O. Cunningham, MD
Hillary V. Kunins, MD, MPH, MS
Robert J. Roose, MD, MPH
Rashiah T. Elam, MD
Nancy L. Sohler, PhD, MPH
Publikationsdatum: 01.09.2007
Verlag: Springer-Verlag
Erschienen in: Journal of General Internal Medicine / Ausgabe 9/2007
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-007-0264-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Barriers to Obtaining Waivers to Prescribe Buprenorphine for Opioid Addiction Treatment Among HIV Physicians

Abstract

Background

Objective

Design

Participants

Approach

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Background

Objective

Design

Participants

Approach

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2007

The TennCare Graduate Medical Education Plan: Ten Years Later

Patient, Physician, Pharmacy, and Pharmacy Benefit Design Factors Related to Generic Medication Use

Internists, Epidemics, Outbreaks, and Bioterrorist Attacks

Update in Women’s Health

The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs

Reliability, Validity and Responsiveness of the Syncope Functional Status Questionnaire

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin